CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home Reports Switching from Herceptin or other Trastuzumab Biosimilars to Biosimilar Ogviri
Back to Reports

Switching from Herceptin or other Trastuzumab Biosimilars to Biosimilar Ogviri

Last updated: February 4, 2019
Project Number: RA1009-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with early breast cancer (EBC)?
  2. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with metastatic breast cancer (MBC)?
  3. What is the clinical effectiveness of switching from Herceptin or other biosimilars to Ogivri for patients with metastatic gastric cancer (MGC)?

Key Message

No relevant literature was identified regarding the clinical effectiveness of switching from Ogivri or other biosimilars to Herceptin for patients with EBC, MBC or MGC.

Files

Switching from Herceptin or other Trastuzumab Biosimilars to Biosimilar Ogviri

Rapid Response

Reference List

  • Published: February 4, 2019

Related Content